Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck reorganises European operations

Appoints João Rocha and Michael Quiqueran-Beajeu as regional vice presidents

Lundbeck has split its European activities into two regional units and appointed João Rocha and Michael Quiqueran-Beajeu to lead them.

The Danish pharma company has promoted Rocha from country manager in Brazil and regional vice president for Latin America to vice president of its new Region West unit.

Prior to joining Lundbeck he served with Merck and Schering-Plough and in his new role will have responsibility for Lundbeck's commercial activities in the majority of Western European countries.

Meanwhile Quingueran-Beajeuwill joins Lundbeck from Genzyme, where he was senior vice president and general manager for Northern Europe. He has more than 20 years of experience in the European pharmaceutical industry and previously worked for companies such as Sandoz and Roche.

He will now lead Lundbeck's operations in Eastern Europe as well as Turkey and Russia.

"Europe is still Lundbeck's largest market, and with our growing drug portfolio and several new launches in the near future, it is important that we consolidate and strengthen our European organisation," said Marie-Laure Pochon, Lundbeck's executive vice president for commercial operations.

"With our new structure and the appointment of João Rocha and Michael Quiqueran-Beaujeu, who both bring with them many years of experience and impressive results, I am convinced that we have a set-up that gives us the optimal conditions for success in developing and expanding the Lundbeck business."

New products on the horizon include the company's alcohol dependence treatment Selincro (nalmefene), which was filed for European approval in December.

And earlier this year Lundbeck launched its antipsychotic Sycrest (asenapine) in UK, following its EU debut in Denmark last year.

Europe accounts for 50 per cent of Lundbeck's revenue, which last year rose two per cent to DKK 8bn (€1.1bn) in 2011.

10th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics